FDA Brief

Warning letters Drugs

FDA warning letter to

FluxxLab LLC

High riskIssued Aug 4, 2022Posted Aug 5, 2022Center for Drug Evaluation and Research | CDER

FDA and FTC warned FluxxLab that its COVID-19 and CBDA/CBD tinctures are unapproved, misbranded drugs marketed with unsupported COVID-19 claims.

What happened

FDA reviewed https://fluxxlab.com/ on July 12, 2022, and FTC reviewed it on August 1, 2022. FDA says the website offered Covid-19 Immune Support Tincture and CBDA+CBD Oil Tincture for sale and made claims that they could prevent, treat, diagnose, or cure COVID-19. FDA cited these as unapproved new drugs and misbranded drugs; FTC said the health claims lacked competent and reliable scientific evidence.

What FDA found

  1. FDA says the tinctures are unapproved new drugs because they are sold with claims to prevent, treat, diagnose, or cure COVID-19 without FDA approval.

    section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. FDA says the products are misbranded drugs.

    section 502 of the FD&C Act, 21 U.S.C. § 352
  3. FDA says introducing these products into interstate commerce is prohibited.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. FTC says the company advertised that the products can prevent, treat, or cure COVID-19 without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. § 41 et seq.

What FDA wants

FDA asks the company to immediately stop selling any unapproved or unauthorized products for COVID-19. Within 48 hours, the company must email COVID-19-Task-Force-CDER@fda.hhs.gov describing steps taken to correct the violations and prevent recurrence, with supporting documents; FTC separately requires certification within 48 hours that unsubstantiated claims have ceased.

Who should pay attention

  • consumers who buy COVID-19-related supplements online
  • online supplement and CBD brands making disease claims
  • retailers or marketplaces that list tinctures with COVID-19 claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk